Ring Therapeutics utilizes its Anellogy™ platform to engineer anellovirus-based gene therapies that can effectively target specific cells and tissues while evading the immune system. This approach addresses the need for safe and versatile delivery mechanisms for diverse therapeutic modalities in patients with significant medical needs.
Funding
$253.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current gene therapy delivery methods often struggle with immune system recognition and limited targeting capabilities, hindering their effectiveness and safety in treating various diseases. Traditional viral vectors can trigger immune responses, reducing therapeutic impact and potentially causing adverse effects.
Solution
Ring Therapeutics is developing anellovirus-based gene therapies using its Anellogy™ platform to overcome the limitations of existing delivery methods. Anelloviruses are engineered to target specific cells and tissues while evading the immune system, offering a safer and more versatile approach. The Anellogy™ platform harnesses the natural properties of anelloviruses, including their diversity, ubiquity within human tissues, and ability to avoid immune detection, to create therapies with improved tissue tropism, payload versatility, potency, and redosability. This approach aims to deliver diverse therapeutic modalities effectively to patients with significant medical needs.
Target Audience
The primary target audience includes patients with genetic diseases, cancer, and other conditions requiring targeted and safe gene therapy delivery, as well as pharmaceutical companies developing novel gene therapies.
Features
- Anellovirus-based vectors for targeted gene therapy delivery
- Anellogy™ platform for engineering anelloviruses with specific tissue tropisms
- Immune evasion properties to minimize immune response and enhance therapeutic efficacy
- Versatile payload capacity for delivering various therapeutic modalities
- Potential for redosability, enabling repeated treatments without immune interference